Katherine Beebe DeVarney's most recent trade in Titan Pharmaceuticals, Inc. (de) was a trade of 100,000 Option to Purchase Common Stock done . Disclosure was reported to the exchange on July 26, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Titan Pharmaceuticals, Inc... | Katherine Beebe DeVarney | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 100,000 | 100,000 | - | - | Option to Purchase Common Stock | |
| Titan Pharmaceuticals, Inc... | Katherine Beebe DeVarney | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2023 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Titan Pharmaceuticals, Inc... | Katherine Beebe DeVarney | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 55,000 | 55,000 | - | - | Option to Purchase Common Stock | |
| Titan Pharmaceuticals, Inc... | Katherine Beebe DeVarney | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 150,000 | 150,000 | - | - | Option to Purchase Common Stock |